Mesoblast plunges 30 per cent ahead of milestone meeting

Mesoblast plunges 30 per cent ahead of milestone meeting

The Age

Published

The stem cell treatment maker is under pressure as it faces a crucial test to get its flagship drug approved by the US Food and Drug Administration.

Full Article